Literature DB >> 16103167

Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion.

Samvel R Mkrtchyan1, Ruben M Markosyan, Michael T Eadon, John P Moore, Gregory B Melikyan, Fredric S Cohen.   

Abstract

Human immunodeficiency virus (HIV) Env-induced fusion is highly temperature dependent. When effector and target cells were coincubated at 37 degrees C, there was a kinetic delay before fusion commenced. When effector and target cells were coincubated for varied times at 23 degrees C, a temperature that does not permit fusion, a temperature-arrested stage was created. Raising temperature to 37 degrees C from the 23 degrees C intermediate eliminated the kinetic delay. Inhibitors (T22, AMD3100, and Sch-C) that block fusion by binding chemokine receptors were added after creating the intermediate so as to assess the extent of engagement between gp120 and chemokine receptors at that stage. For both CXCR4 and CCR5 as coreceptors, increasingly long times of coincubation at 23 degrees C reduced the efficacy of the coreceptor-binding inhibitors in blocking fusion. This implies that an increasing number of ternary Env/CD4/coreceptor complexes form over time at 23 degrees C. It also shows that ternary complex formation has a lower temperature threshold than the downstream steps that include Env folding into a six-helix bundle; this provides an experimental means to separate coreceptor binding by gp120 from the subsequent refolding of gp41 into a six-helix bundle structure. As the time of cell coincubation at 23 degrees C was prolonged, more cells quickly fused upon the raising of the temperature to 37 degrees C, and the increase quantitatively correlated with the greater percentage of fusion that was resistant to drugs. Therefore the pronounced kinetic delay in HIV Env-induced fusion is caused predominantly by the time needed for ternary complexes to form.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103167      PMCID: PMC1193594          DOI: 10.1128/JVI.79.17.11161-11169.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists.

Authors:  John O Trent; Zi-xuan Wang; James L Murray; Wenhai Shao; Hirokazu Tamamura; Nobutaka Fujii; Stephen C Peiper
Journal:  J Biol Chem       Date:  2003-09-04       Impact factor: 5.157

2.  Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusion.

Authors:  Janet E Lineberger; Renee Danzeisen; Daria J Hazuda; Adam J Simon; Michael D Miller
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion.

Authors:  L G Abrahamyan; R M Markosyan; J P Moore; F S Cohen; G B Melikyan
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

4.  The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor.

Authors:  Christian Watson; Stephen Jenkinson; Wieslaw Kazmierski; Terry Kenakin
Journal:  Mol Pharmacol       Date:  2005-01-11       Impact factor: 4.436

5.  Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry.

Authors:  Sigrid Hatse; Katrien Princen; Kurt Vermeire; Lars-Ole Gerlach; Mette M Rosenkilde; Thue W Schwartz; Gary Bridger; Erik De Clercq; Dominique Schols
Journal:  FEBS Lett       Date:  2003-07-10       Impact factor: 4.124

6.  Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions.

Authors:  Ping Zhu; Elena Chertova; Julian Bess; Jeffrey D Lifson; Larry O Arthur; Jun Liu; Kenneth A Taylor; Kenneth H Roux
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-10       Impact factor: 11.205

7.  Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

Authors:  Fotini Tsamis; Svetlana Gavrilov; Francis Kajumo; Christoph Seibert; Shawn Kuhmann; Tom Ketas; Alexandra Trkola; Anadan Palani; John W Clader; Jayaram R Tagat; Stuart McCombie; Bahige Baroudy; John P Moore; Thomas P Sakmar; Tatjana Dragic
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

8.  Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates.

Authors:  Hana Golding; Marina Zaitseva; Eve de Rosny; Lisa R King; Jody Manischewitz; Igor Sidorov; Miroslaw K Gorny; Susan Zolla-Pazner; Dimiter S Dimitrov; Carol D Weiss
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation.

Authors:  Ruben M Markosyan; Fredric S Cohen; Grigory B Melikyan
Journal:  Mol Biol Cell       Date:  2003-03       Impact factor: 4.138

10.  Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor.

Authors:  Mette M Rosenkilde; Lars-Ole Gerlach; Janus S Jakobsen; Renato T Skerlj; Gary J Bridger; Thue W Schwartz
Journal:  J Biol Chem       Date:  2003-10-28       Impact factor: 5.157

View more
  39 in total

1.  An antibody directed against the fusion peptide of Junin virus envelope glycoprotein GPC inhibits pH-induced membrane fusion.

Authors:  Joanne York; Jody D Berry; Ute Ströher; Qunnu Li; Heinz Feldmann; Min Lu; Meg Trahey; Jack H Nunberg
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

2.  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

Authors:  Thomas J Ketas; Sophie Holuigue; Katie Matthews; John P Moore; Per Johan Klasse
Journal:  Virology       Date:  2011-10-22       Impact factor: 3.616

3.  The six-helix bundle of human immunodeficiency virus Env controls pore formation and enlargement and is initiated at residues proximal to the hairpin turn.

Authors:  Ruben M Markosyan; Michael Y Leung; Fredric S Cohen
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

Review 4.  Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme.

Authors:  Judith M White; Sue E Delos; Matthew Brecher; Kathryn Schornberg
Journal:  Crit Rev Biochem Mol Biol       Date:  2008 May-Jun       Impact factor: 8.250

5.  Distinct requirements for HIV-cell fusion and HIV-mediated cell-cell fusion.

Authors:  Naoyuki Kondo; Mariana Marin; Jeong Hwa Kim; Tanay M Desai; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2015-01-14       Impact factor: 5.157

6.  Significant differences in cell-cell fusion and viral entry between strains revealed by scanning mutagenesis of the C-heptad repeat of HIV gp41.

Authors:  Barbara Diaz-Aguilar; Karen Dewispelaere; Hyun Ah Yi; Amy Jacobs
Journal:  Biochemistry       Date:  2013-05-07       Impact factor: 3.162

7.  Multifaceted mechanisms of HIV-1 entry inhibition by human α-defensin.

Authors:  Lusine H Demirkhanyan; Mariana Marin; Sergi Padilla-Parra; Changyou Zhan; Kosuke Miyauchi; Maikha Jean-Baptiste; Gennadiy Novitskiy; Wuyuan Lu; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

8.  A lectin isolated from bananas is a potent inhibitor of HIV replication.

Authors:  Michael D Swanson; Harry C Winter; Irwin J Goldstein; David M Markovitz
Journal:  J Biol Chem       Date:  2010-01-15       Impact factor: 5.157

9.  Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.

Authors:  Gregory B Melikyan; Marc Egelhofer; Dorothee von Laer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.

Authors:  Behzad Etemad; Angela Fellows; Brenda Kwambana; Anupa Kamat; Yang Feng; Sandra Lee; Manish Sagar
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.